Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

NCT07378644 is registered in ClinicalTrials.gov with Skyhawk Therapeutics, Inc. as lead sponsor.

NCT NCT07378644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07378644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Lead sponsor
Skyhawk Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 6, 2026
Completion date
August 31, 2029
Enrollment
400 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease